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Abstract:  One new sterol, crassarosterol A (1), and four new steroidal glycosides, 
crassarosterosides A–D (2–5) were isolated from the Formosan soft coral Sinularia crassa. 
The absolute configuration of 1 was determined using the Mosher’s method. The absolute 
configurations for the sugar moieties of 2–5 were determined by HPLC analysis on the  
o-tolylthiocarbamates derived from the liberated sugar after acid hydrolysis. Compounds 2 
and  4  could  significantly inhibit the expression of pro-inflammatory iNOS protein at   
10 µM. In contrast, 1–3 were found to stimulate the expression of COX-2 protein at this 
concentration. Steroids 1 and 4 also showed cytotoxicity toward the selected human liver 
cancer cells. 
Keywords: Sinularia crassa; crassarosterosides A–D; crassarosterol A; anti-inflammatory 
activity; o-tolylthiocarbamate 
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1. Introduction  
Soft corals have proven to be a rich source of terpenoids [1]. We previously have isolated a series of 
bioactive cembrane- [2–4] and norcembrane- [5–8] diterpenoids from the Formosan soft corals of the 
genus Sinularia. Previous chemical investigations on the soft coral Sinularia crassa have led to the 
isolation of structurally unique steroids  and cembranoids,  from  which some have been shown to 
exhibit anti-inflammatory  [9,10]  and  5α-reductase inhibitory activities  [11],  respectively. Our 
continuing chemical investigation on S. crassa has led to the isolation of one new sterol, crassarosterol 
A (1), and four new steroidal glycosides, crassarosterosides A–D (2–5) (Figure 1). The structures of  
1–5 have been established by extensive spectroscopic analysis, including 2D NMR (
1H–
1H COSY, 
HMQC, HMBC, and NOESY), chemical methods, and HPLC. The effect of 1–4 on the expression of 
the pro-inflammatory inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) proteins 
in  lipopolysaccharide (LPS)-stimulated RAW264.7 macrophage cells and the cytotoxicity of 
compounds 1–5 against a panel of cancer cell lines including human liver carcinoma (HepG2 and 
HepG3), human breast carcinoma (MCF-7 and MDA-MB-231), and human lung carcinoma (A-549) 
were evaluated in order to discover bioactive natural products. 
Figure 1. Structures of compounds 1–5. 
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2. Results and Discussion 
The HRESIMS of crassarosterol A (1)  exhibited a pseudomolecular ion peak at m/z  453.3342  
[M + Na]
+, consistent with a molecular formula of C28H46O3 and requiring six degrees of unsaturation. 
The 
13C NMR and DEPT spectroscopic data (Table 1) displayed 28 carbon signals, including five 
methyls, nine methylenes, ten methines, and four quaternary carbons. The IR spectrum revealed the 
presence of hydroxy groups (3389 cm
–1). The carbon resonances at δ 141.2 (C), 121.3 (CH), 156.9 (C), 
and  106.3 (CH2) suggested the presence of two double bonds. The above data coupled with the 
characteristic 
1H NMR signals for methyl groups at  δ  0.92 (3H, s), 1.18 (3H, s), 1.04 (3H, d,   
J = 6.8 Hz), and 1.03 (6H, d, J = 7.2 Hz) and signals for olefinic protons at δH 5.41 (1H, d, J = 5.6 Hz), Mar. Drugs 2012, 10                                                 
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4.76 (1H, s), and 4.70 (1H, s) (Table 2) suggested 1 to be a member of the 24-methylenecholesterol 
class [12,13]. The 
1H−
1H COSY correlations allowed the assignment of four separated spin systems 
(Figure 2). The presence of an sp
2 methylene substituent at C-24 was further confirmed by the HMBC 
correlations from H2-28 to C-23, C-24, and C-25  (Figure  2).  Likewise, the steroidal nucleus was 
confirmed by the HMBC correlations from H3-18 to C-12, C-13, C-14, and C-17 and H3-19 to C-1,  
C-5, C-9, and C-10. The NOE correlations between H3-19/H-1β, H-3/H-1α, and H3-19/H-11 suggested 
the α and β orientations for H-3 and H-11, respectively. The absence of an NOE correlation between 
H3-18/H-17 and the presence of the correlation between H-17/H-16, H-16/H-14, and H-14/H-9 
suggested the α orientation for H-9, H-14, H-16, and H-17. Moreover, the β orientation for H-20 was 
evidenced from the NOE correlations between H3-18/H-20, H3-18/H-12a, and H3-21/H-12a.  The 
absolute configuration of 1 was determined by the application of Mosher’s method [14]. Analysis of 
the
 1H NMR data of esters 1a and 1b resulted in the determination of a 3S configuration (Figure 3). 
Table 1. 
13C NMR spectroscopic data of compounds 1−5. 
position  1
a  2
b  3
b  4
a  5
a 
1  39.1, CH2  39.2, CH2  39.2, CH2  39.2, CH2  37.1, CH2 
2  31.8, CH2  29.7, CH2  29.5, CH2  29.7, CH2  29.6, CH2 
3  71.8, CH  78.2, CH  77.8, CH  78.2, CH  78.3, CH 
4  42.7, CH2  39.1, CH2  39.0, CH2  39.1, CH2  38.8, CH2 
 5  141.2, C  140.6, C  140.7, C  140.5, C  140.3, C 
6  121.3, CH  121.7, CH  121.6, CH  121.8, CH  122.1, CH 
7  31.9, CH2  31.8, CH2  31.8, CH2  31.8, CH2  31.5, CH2 
8  31.4, CH  31.3, CH  31.3, CH  31.3, CH  30.4, CH 
9  56.9, CH  56.8, CH  56.9, CH  56.8, CH  50.3, CH 
10  38.1, C  38.3, C  38.3, C  38.3, C  36.9, C 
11  68.9, CH  68.9, CH  68.9, CH  68.9, CH  21.0, CH2 
12  51.4, CH2  51.4, CH2  51.4, CH2  51.4, CH2  36.2, CH2 
13  42.9, C  42.9, C  42.9, C  42.9, C  47.4, C 
14  53.7, CH  53.6, CH  53.6, CH  53.6, CH  57.9, CH 
15  36.3, CH2  36.3, CH2  36.3, CH2  36.3, CH2  31.0, CH2 
16  72.5, CH  72.5, CH  72.5, CH  72.5, CH  123.8, CH 
17  61.2, CH  61.2, CH  61.2, CH  61.2, CH  160.9, CH 
18  14.0, CH3  14.1, CH3  14.1, CH3  14.1, CH3  18.1, CH3 
19  19.1, CH3  19.0, CH3  19.0, CH3  19.0, CH3  19.3, CH3 
20  29.6, CH  29.6, CH  29.6, CH  29.6, CH  76.0, C 
21  18.2, CH3  18.2, CH3  18.2, CH3  18.2, CH3  29.6, CH3 
22  34.8, CH2  34.8, CH2  34.7, CH2  34.7, CH2  49.1, CH2 
23  31.2, CH2  31.2, CH2  31.2, CH2  31.2, CH2  29.6, CH 
24  156.9, C  156.9, C  156.9, C  156.9, C  45.5, CH 
25  34.1, CH  34.0, CH  34.0, CH  34.0, CH  30.9, CH 
26  21.8, CH3  21.8, CH3  21.8, CH3  21.8, CH3  20.9, CH3 
27  21.9, CH3  21.9, CH3  21.9, CH3  21.9, CH3  21.5, CH3 
28  106.3, CH2  106.3, CH2  106.3, CH2  106.4, CH2  11.6, CH3 
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Table 1. Cont. 
29          15.7, CH3 
1’    97.4, CH  94.7, CH  97.2, CH  97.2, CH 
2’    74.0, CH  68.6, CH  70.1, CH  70.1, CH 
3’    66.9, CH  72.1, CH  69.5, CH  69.5, CH 
4’    70.9, CH  72.4, CH  73.0, CH  73.0, CH 
5’    65.8, CH  65.3, CH  65.2, CH  65.2, CH 
6’    16.0, CH3  16.1, CH3  16.2, CH3  16.2, CH3 
OAc    170.9, C  171.5, C  171.3, C  171.3, C 
    21.2, CH3  21.1, CH3  20.8, CH3  20.8, CH3 
a Spectra were measured in CDCl3 (100 MHz); 
b Spectra were measured in CDCl3 (125 MHz). 
Figure 2. Selected 
1H−
1H COSY (▬) and HMBC (→) correlations of 1 and 5 and the 
fucose residue in 1–5. 
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Analysis of the HRESIMS and 
13C NMR spectroscopic data of crassarosteroside A (2) suggested a 
molecular formula of C36H58O8. The IR spectrum of 2 showed the presence of hydroxy (3461 cm
−1) 
and carbonyl (1741 cm
−1) groups. The latter was identified as an acetoxy group according to the 
carbon resonances at δ 170.9 (C) and 21.2 (CH3) (Table 1). The 
1H NMR spectroscopic data of 2 
showed characteristic methyl signals at δ 0.92 (3H, s), 1.18 (3H, s), 1.04 (3H, d, J = 6.8 Hz), 1.03 (6H, 
d, J = 7.0 Hz), 5.41 (1H, d, J = 5.6 Hz), 4.76 (1H, s), and 4.70 (1H, s) (Table 2), revealing that 2 has 
the same 24-methylenecholesterol skeleton as that of 1. By excluding the steroidal moiety and the 
acetoxy group, the remaining six carbons [δ 97.4 (CH), 74.0 (CH), 66.9 (CH), 70.9 (CH), 65.8 (CH), 
and 16.0 (CH3)] were ascribed to the presence of a 6’-deoxyhexose residue. The sugar residue was 
deduced as an α-fucopyranose on the basis of 2D NMR analysis (Figure 2) and the coupling constants 
of 
3JH-1’,H-2’ (4.0 Hz), 
3JH-2’,H-3’ (10.0 Hz), 
3JH-3’,H-4’ (3.5 Hz), and 
3JH-4’,H-5’ (<1 Hz) (Table 2) [12,15,16]. 
The acetoxy group attached at C-2’  of the α-fucose residue was  evidenced from the downfield 
chemical shift of H-2’ (δ 5.07), which was confirmed by the HMBC correlations from this proton to 
the  acetate  carbonyl carbon. The HMBC correlation from H-1’  to C-3  revealed  that the α-fucose Mar. Drugs 2012, 10                                                 
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residue was attached at C-3 of the steroidal aglycone. The absolute configuration of the sugar moiety 
in 2 was determined by reversed phase HPLC analysis of its o-tolylthiocarbamate [17]. The liberated 
fucose from acid hydrolysis of 2 was treated with L-cysteine methyl ester followed by reaction with  
o-tolylisothiocyanate to afford the corresponding o-tolylthiocarbamate derivative. The retention time 
of the liberated sugar derivative by HPLC analysis was found to be consistent with that of a standard  
L-fucose derivative.  
Crassarosteroside B (3) gave the same molecular formula as that of 2 based on the analysis of the 
HRESIMS and 
13C NMR spectroscopic data (Table 1). The NMR spectroscopic data of 3 were similar 
to those of 2, with some exceptions for those of the sugar residue. An HMBC correlation from the 
anomeric proton at δ 5.12 (H-1’) to the carbon signal at δ 77.8 (C-3) connected the fucose residue to  
C-3 of the steroidal aglycone. The downfield proton chemical shift at δ 4.87 (1H, dd, J = 10.5, 4.0 Hz) 
was ascribed to the presence of an acetoxy group at C-3’ (Table 2). The detailed 2D NMR analysis 
confirmed the above elucidation. Likewise, the L-fucose residue was deduced according to RP HPLC 
analysis of the corresponding o-tolylthiocarbamate as described above. 
Figure 3. 
1H NMR chemical shift differences of MTPA esters of 1. 
δ = δ (S) − δ (R) MTPA ester
- 0.03
- 0.01
+ 0.11 + 0.01
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H H
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Crassarosteroside C (4) was assigned the same molecular formula as those of 2 and 3. A comparison 
of NMR spectroscopic data of 4 with those of 2 and 3 revealed that an acetoxy group should be located 
at C-4’ of the fucose residue (Tables 1 and 2). This was evidenced by the 
1H NMR shift of H-4’ at 5.20 
(1H, d, J = 2.8 Hz). In the same manner, RP HPLC anslysis of the corresponding o-tolylthiocarbamate 
derived from the hydrolyte of 4 allowed the determination of the L-fucose moiety.  
The HRESIMS and 
13C NMR spectroscopic data of crassarosteroside D (5) established a molecular 
formula of C37H60O7. The presence of an acetoxy group was evidenced by the 
1H NMR signal at δ 2.17 
(3H, s) (Table 1) and 
13C NMR signals at δ 171.3 (C) and 20.8 (CH3) (Table 2) as well as the IR 
absorption band at 1737 cm
−1. The NMR spectroscopic data for the sugar moiety of 5 were quite 
similar to those of 4, suggesting that they shared the same 4’-O-acetylfucose residue. Except for the 
sugar moiety, the remaining 29 carbon signals as well as the characteristic methyl signals at δ 1.00 
(3H, s), 1.05 (3H, s), 1.38 (3H, s), 0.86 (3H, d, J = 6.4 Hz), 0.89 (3H, d, J = 6.4 Hz), 0.76 (3H, d,  
J = 6.8 Hz), and 0.78 (3H, d, J = 6.4 Hz) (Table 2) revealed that the aglycone of 5 should have a C29 
steroidal skeleton [18]. The 23,24-dimethyl-20-hydroxy side chain was deduced by the 
1H−
1H COSY 
correlations from H2-22 to H3-29 through H-23, from H-24 to both H3-26 and H3-27, and from H-24 to 
H3-28 as well as the HMBC correlations from H3-21 to C-17, C-20, and C-22 and H3-29 to C-22, C-23, Mar. Drugs 2012, 10                                                 
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and C-24. This rare steroidal side chain is the same as that of sarcophytosterol isolated previously by 
us from the soft coral Lobophytum sarcophytoides [18].
 The NMR spectroscopic data for the aglycone 
moiety of 5 are almost the same as those of sarcophytosterol, except for some minor variations in 
1H 
and 
13C chemical shifts at C-2, C-3, and C-4 between both compounds. This is due to the attachment of 
the  sugar  residue at C-3 of the steroidal  aglycone. Similarly,  HPLC analysis of the relevant  
o-tolylthiocarbamate derived from the hydrolysis of 5 suggested the presence of L-fucose. 
Table 2. 
1H NMR spectroscopic data of compounds 1−5. 
＃  1, δH (J in Hz)
a  2, δH (J in Hz)
b  3, δH (J in Hz)
b  4, δH (J in Hz)
a  5, δH (J in Hz)
a 
1 
 
a: 2.55, dt  
(13.6, 3.6) 
a: 2.58, dt  
(13.5, 3.5) 
a: 2.56, dt  
(13.5, 3.5) 
a: 2.58, dt  
(14.0, 3.6) 
a: 1.86, m 
  b: 1.16, m  b: 1.16, m  b: 1.16, m  b: 1.16, m  b: 1.10, m 
2  a: 1.81, m  a: 1.85, m  a: 1.79, m  a: 1.81, m  a: 1.89, m 
  b: 1.58, m  b: 1.65, m  b: 1.66, m  b: 1.64, m  b: 1.60, m 
3  3.53, m  3.51, m  3.43, m  3.49, m  3.49, m 
4  a: 2.30, m  a: 2.36, m  2.24, m  a: 2.36, m  a: 2.36, m 
  b: 2.26, m  b: 2.26, m    b: 2.26, m  b: 2.24, m 
6  5.41, d (5.6)  5.41, d (5.5)  5.40, d (5.5)  5.41, d (5.6)  5.38, br d (3.2) 
7  a: 1.99, m  a: 1.99, m  a: 1.98, m  a: 1.99, m  a: 2.01, m 
  b: 1.54, m  b: 1.56, m  b: 1.54, m  b: 1.54, m  b: 1.61, m 
8  1.50, m  1.50, m  1.49, m  1.50, m  1.66, m 
9  0.99, m  0.99, m  0.97, m  0.98, m  1.01, m 
11 
 
4.07, td  
(10.8, 4.8) 
4.07, m  4.06, m 
4.07, td  
(10.8, 4.4) 
1.59, m 
12  a: 2.31, m  a: 2.31, m  a: 2.31, m  a: 2.31, m  a: 2.10, m 
  b: 1.18, m  b: 1.18, m  b: 1.18, m  b: 1.18, m  b: 1.59, m 
14  0.98, m  0.98, m  0.98, m  0.98, m  1.41, m 
15  a: 2.24, m  a: 2.24, m  a: 2.23, m  a: 2.23, m  a: 2.08, m 
  b: 1.17, m  b: 1.16, m  b: 1.17, m  b: 1.16, m  b: 1.87, m 
16  4.40, m  4.40, m  4.40, m  4.40, m  5.50, br s 
17  1.07, m  1.07, m  1.07, m  1.07, m   
18  0.92, s  0.92, s  0.92, s  0.92, s  1.00, s 
19  1.18, s  1.18, s  1.17, s  1.18, s  1.05, s 
20  1.86, m  1.86, m  1.86, m  1.87, m   
21  1.04, d (6.8)  1.04, d (6.8)  1.04, d (6.5)  1.04, d (6.4)  1.38, s 
22  a: 1.68, m  a: 1.68, m  a: 1.68, m  a: 1.67, m  a: 1.59, m 
  b: 1.22, m  b: 1.22, m  b: 1.22, m  b: 1.22, m  b: 1.48, m 
23  a: 2.18, m  a: 2.18, m  a: 2.18, m  a: 2.18, m  1.82, m 
  b: 1.95, m  b: 1.95, m  b: 1.95, m  b: 1.95, m   
24          1.06, m 
25  2.24, m  2.25, m  2.25, m  2.25, m  1.42, m 
26  1.03, d (7.2)  1.03, d (7.0)  1.03, d (7.0)  1.03, d (6.8)  0.86, d (6.4) 
27  1.03, d (7.2)  1.03, d (7.0)  1.03, d (7.0)  1.03, d (6.8)  0.89, d (6.4) 
28  a: 4.76, s  a: 4.76, s  a: 4.76, s  a: 4.76, s  0.76, d (6.8) 
  b: 4.70, s  b: 4.70, s  b: 4.70, s  b: 4.70, s   
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Table 2. Cont. 
29          0.78, d (7.2) 
1’    5.02, d (4.0)  5.12, d (4.0)  5.04, d (4.0)  5.04, d (4.0) 
2’ 
 
 
5.07, dd  
(10.0, 4.0) 
4.02, m 
 
3.93, dd  
(10.0, 4.0) 
3.93, dd (10.0, 4.0) 
 
3’ 
 
 
3.91, ddd  
(11.5,10.0, 3.5) 
4.87, dd  
(10.5, 4.0) 
3.74, br d (10.0) 
 
3.74, dd (10.0, 2.4) 
 
4’    3.84, br s  3.82, br s  5.20, d (2.8)  5.21, d (2.4) 
5’    4.11, q (7.0)  4.12, q (6.5)  4.12, q (6.4)  4.12, q (6.4) 
6’    1.25, d (7.0)  1.27, d (6.5)  1.13, d (6.4)  1.14, d (6.4) 
OAc    2.18, s  2.15, s  2.17, s  2.17, s 
3’-OH   1.90, d (11.5)       
4’-OH   1.89, br s  2.18, br s     
a Spectra were measured in CDCl3 (400 MHz); 
b Spectra were measured in CDCl3 (500 MHz). 
Figure 4. Effect of compounds 1–4 at 10 μM on the LPS-induced pro-inflammatory iNOS 
and on COX-2 protein expression of RAW264.7 macrophage cells by immunoblot 
analysis. (A) Immunoblots for iNOS and β-actin, and relative density of iNOS. 
(B) Immunoblots for COX-2 and β-actin, and relative density of COX-2. The values are  
means ± SEM (n = 6). The relative intensity of the LPS alone stimulated group was taken 
as 100%. Under the same experimental conditions, 10 μM CAPE (caffeic acid phenethyl 
ester; Sigma Chemical Company, St. Louis, MO) reduced the levels of the iNOS and 
COX-2 protein to 0.8 ± 4.5% and 75.6 ± 12.2%, respectively, relative to the control cells 
stimulated with LPS. *Significantly different from LPS alone stimulated group   
(*P < 0.05). 
   
The absolute configuration of sterol 1 has been established by Mosher’s method in the present work. 
On the basis of biogenesis, the steroidal moieties of the glycosides 2–5  should possess the same 
absolute configurations as shown in the formulae. Cytotoxicity of steroids 1–5 against HepG2, HepG3, 
MCF-7,  MDA-MB-231,  and  A-549  cancer cell lines was evaluated. The results showed that 1 
exhibited cytotoxicity toward HepG2 cancer cell line with an IC50 value of 14.9 µM, while 4 also Mar. Drugs 2012, 10                                                 
 
 
446 
showed cytotoxicity toward HepG2  and HepG3 cell lines with IC50 values of 17.6 and 18.9 µM, 
respectively. The other compounds were found to be inactive (IC50 > 20 μM) toward the above cancer 
cell lines after 72 h exposure. The effect of steroids 1–4 on the expression of pro-inflammatory iNOS 
and COX-2 proteins in RAW264.7 macrophage cells stimulated with LPS was also evaluated using 
immunoblot analysis. At a concentration of 10 µM (Figure 4), steroid 2 was found to significantly 
reduce the level of  iNOS protein to 12.9  ±  4.3%  and  4  could reduce the iNOS espression to   
50.1 ± 6.3%. However, these compounds could not effectively reduce the level of COX-2. On the 
contrary, 1–3 were found to stimulate the expression of COX-2. 
3. Experimental Section 
3.1. General Experimental Procedures 
The melting point was determined using a Fisher-Johns melting point apparatus. Optical rotations 
were determined with a JASCO P1020 digital polarimeter. IR spectrum was obtained on a JASCO 
FT/IR-4100 spectrophotometer. The NMR spectra were recorded on a Varian 400 MR NMR or Varian 
Unity INOVA 500 FT-NMR instrument at 400 or 500 MHz for 
1H (referenced to TMS, δH 0.00 ppm 
for CDCl3) and 100 or 125 MHz for 
13C (referenced to δC 77.0 for CDCl3). ESIMS and HRESIMS 
were recorded by ESI FT-MS on a Bruker  APEX II mass spectrometer. Silica gel 60 (Merck,   
230−400 mesh) and LiChroprep RP-18 (Merck, 40–63 μm) were used for column chromatography. 
Precoated silica gel plates (Merck, Kieselgel 60 F254, 0.25 mm) and precoated RP-18 F254S plates 
(Merck, 1.05560) were used for TLC analyses. High-performance liquid chromatography (HPLC) was 
performed on a Hitachi L-7100 pump equipped with a Hitachi L-7400 UV detector at 210 nm and a 
semi-preparative reversed-phase column (Merck, Hibar Purospher RP-18e, 5 μm, 250 × 10 mm). 
3.2. Animal Material 
The soft coral Sinularia crassa was collected by hand using scuba off the coast of Sansiantai, 
Taitung county, Taiwan, in July 2008, at a depth of 10 m, and was stored in a freezer. This soft coral 
was identified by one of the authors (C.-F.D.). A voucher specimen (specimen no. SST-03) was 
deposited in the Department of Marine Biotechnology and Resources, National Sun Yat-sen University.  
3.3. Extraction and Isolation 
The frozen bodies of S. crassa (1.1 kg fresh wt) were minced and extracted with EtOH (3 × 2 L). 
The organic extract was concentrated to an aqueous suspension and was further partitioned between 
EtOAc and H2O. The EtOAc extract (17.0 g) was fractionated by open column chromatography on 
silica gel using n-hexane–EtOAc  and EtOAc–MeOH mixtures of increasing polarity to yield   
32 fractions. Fractions 25, eluting with EtOAc–MeOH (8:1), was further separated by silica gel 
column chromatography with gradient elution (n-hexane–acetone, 8:1 to 2:1) to yield four subfractions 
(25A–25D). Subfraction 25B was subjected to RP-18 column chromatography (MeOH–H2O, gradient, 
50–90%), and subsequently purified by RP-18 HPLC (CH3CN–H2O, 65%) to obtain compounds 1  
(6.6 mg) and 5 (1.2 mg). Compound 4 (1.8 mg) was obtained from subfraction 25C using RP-18 HPLC 
(CH3CN–H2O, 65%). In the same manner, Subfraction 25D was fractionated over RP-18 gel using Mar. Drugs 2012, 10                                                 
 
 
447 
gradient elution (MeOH–H2O, gradient, 50–90%) to yield two subfractions (25D-1 and 25D-2). 
Subfraction 25D-2 was separated by RP-18 HPLC (CH3CN–H2O, 85%) to yield compounds 2  
(1.8 mg) and 3 (1.6 mg). 
Crassarosterol A (1): white powder; [α]
24
D −45 (c 0.66, CHCl3); IR (KBr) vmax 3389, 2962, 2925, 
2854, 1462, 1048, 1024 cm−1; 
13C NMR and 
1H NMR data, see Tables 1  and  2;  
ESIMS m/z 453 [M + Na]
+; HRESIMS m/z 453.3342 [M + Na]
+ (calcd for C28H46O3Na, 453.3344). 
Crassarosteroside A (2): white powder; [α]
24
D −34 (c 0.18, CHCl3); IR (KBr) vmax 3461, 2960, 2928, 
2868, 1741, 1467, 1377, 1244, 1077, 1030 cm−1; 
13C NMR and 
1H NMR data, see Tables 1 and 2; 
ESIMS m/z 641 [M + Na]
+; HRESIMS m/z 641.4027 [M + Na]
+ (calcd for C36H58O8Na, 641.4029). 
Crassarosteroside B (3): white powder; [α]
24
D −17 (c 0.16, CHCl3); IR (KBr) vmax 3388, 2963, 2930, 
2857, 1732, 1458, 1375, 1258, 1041 cm−1; 
13C NMR and 
1H NMR data, see Tables 1 and 2; ESIMS 
m/z 641 [M + Na]
+; HRESIMS m/z 641.4026 [M + Na]
+ (calcd for C36H58O8Na, 641.4029). 
Crassarosteroside C (4): white powder; [α]
24
D −52 (c 0.18, CHCl3); IR (KBr) vmax 3426, 2960, 2930, 
2859, 1735, 1461, 1375, 1247, 1074, 1033 cm−1; 
13C NMR and 
1H NMR data, see Tables 1 and 2; 
ESIMS m/z 641 [M + Na]
+; HRESIMS m/z 641.4026 [M + Na]
+ (calcd for C36H58O8Na, 641.4029). 
Crassarosteroside D (5): white powder; [α]
24
D −45 (c 0.12, CHCl3); IR (KBr) vmax 3440, 2960, 2925, 
2855, 1737, 1461, 1377, 1244, 1074, 1036 cm−1; 
13C NMR and 
1H NMR data, see Tables 1 and 2; 
ESIMS m/z 639 [M + Na]
+; HRESIMS m/z 639.4234 [M + Na]
+ (calcd for C37H60O7Na, 639.4237). 
3.4. Preparation of (S)-and (R)-MTPA Esters of 1 
To a solution of 1 (1.0 mg) in pyridine (0.4 mL) was added (R)-MTPA chloride (25 μL), and the 
mixture was allowed to stand for 3 h at room temperature. The reaction was quenched by the addition 
of 1.0 mL of H2O, and the mixture was subsequently extracted with EtOAc (3 × 1.0 mL). The EtOAc 
layers were combined, dried over anhydrous MgSO4, and evaporated. The residue was subjected to 
short silica gel column chromatography using n-hexane−EtOAc (3:1) to yield the (S)-MTPA ester, 1a 
(0.7 mg). The same procedure was used to prepare the (R)-MTPA ester, 1b (1.0 mg from 1.0 mg of 1), 
with (S)-MTPA chloride. Selected 
1H NMR (CDCl3, 400 MHz) of 1a: δ 7.41−7.52 (5H, m, Ph), 5.48 
(1H, br d, J = 6.0 Hz, H-6), 4.89 (1H, m, H-3), 4.76 (1H, s, H-28a), 4.70 (1H, s, H-28b), 4.41 (1H, m, 
H-16), 4.05 (1H, m, H-11), 3.57 (3H, s, OMe), 2.62 (1H, br d, J = 14.0 Hz, H-1a), 2.48 (1H, m, H-4a), 
1.85 (1H, m, H-2a), 1.17 (3H, s, H3-19), 1.03 (6H, d, J = 7.2 Hz, H3-26 and 27), 0.92 (3H, s, H3-18); 
selected 
1H NMR (CDCl3, 400 MHz) of 1b: δ 7.41−7.53 (5H, m, Ph), 5.47 (1H, br d, J = 5.2 Hz, H-6), 
4.89 (1H, m, H-3), 4.76 (1H, s, H-28a), 4.70 (1H, s, H-28b), 4.41 (1H, m, H-16), 4.06 (1H, m, H-11), 
3.57 (3H, s, OMe), 2.65 (1H, br d, J = 13.6 Hz, H-1a), 2.37 (1H, m, H-4a), 1.77 (1H, m, H-2a), 1.17 
(3H, s, H3-19), 1.03 (6H, d, J = 7.2 Hz, H3-26 and 27), 0.92 (3H, s, H3-18). 
3.5. Determination of Sugar Configuration 
Authentic samples of D-fucose  and  L-cysteine  methyl ester hydrochloride (each  0.5  mg) were 
dissolved in pyridine  (0.1  mL) and heated at 60 °C  for 1 h.  To this  mixture  was added  
o-tolylisothiocyanate (0.5 mg in 0.1 mL pyridine) and heated at 60 °C for additional 1 h. The reaction 
mixture was directly analyzed by reversed-phase HPLC (Mightysil RP-18 GP column; 4.6 × 250 nm; 
25% CH3CN in 50 mM H3PO4; 0.8 mL/min; 35 °C) and detected at 250 nm to give the retention time Mar. Drugs 2012, 10                                                 
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of the o-tolylthiocarbamate of sugar. The retention of the o-tolylthiocarbamate derived from L-fucose, 
L-cysteine methyl ester, and o-tolylisothiocyanate was obtained by the same manner. 
A solution of the glycoside (0.4 mg for each) in 0.6 M HCl/dioxane (1:1 v/v, 0.2 mL) was heated at 
80 °C for 24 h. After cooling, the solution was neutralized with Amberlite IRA-400, and the resin was 
removed by filtration. The filtrate was extracted with EtOAc. The aqueous layer was dried in vacuo 
and  the  afforded  residue was dissolved  in pyridine (0.1 mL) containing L-cysteine methyl ester   
(0.5 mg), followed by heating at 60 °C for 1 h. A 0.1 mL solution of o-tolylisothiocyanate (0.5 mg) in 
pyridine was added to the mixture, which was heated at  60 °C for additional  1 h, to yield the 
corresponding  o-tolylthiocarbamate derivative. Reverse phase HPLC analysis of the   
o-tolylthiocarbamate derivatives derived from the hydrolytes of the glycosides 2–5 showed peaks at 
28.2, 28.0, 28.1, and 27.9 min, respectively, while the tR values for standard L-fucose and D-fucose 
derivatives were observed at 28.0 and 25.4 min, respectively, suggesting the presence of a L-fucose 
residue in 2–5. 
3.6. Cytotoxicity Testing 
Cell lines were purchased from the American Type Culture Collection (ATCC). Compounds were 
assayed for cytotoxicity against human liver carcinoma (HepG2 and HepG3), human breast carcinoma 
(MCF-7  and  MDA-MB-231),  and  human lung carcinoma (A-549) cells using the   
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method [19]. Freshly trypsinized 
cell suspensions were seeded in 96-well microtiter plates at densities of 5000–10000 cells per well 
with tested compounds added from DMSO-diluted stock. After 3 days in culture, attached cells were 
incubated with MTT (0.5 mg/mL, 1 h) and subsequently dissolved in DMSO. The absorbency at  
550 nm was then measured using a microplate reader. The IC50 is the concentration of agent that 
reduced cell growth by 50% under the experimental conditions.  
3.7. In Vitro Anti-Inflammatory Assay 
Macrophage (RAW264.7) cell line was purchased from ATCC. In vitro anti-inflammatory activities 
of tested compounds were measured by examining the inhibition of lipopolysaccharide (LPS) induced 
upregulation of iNOS and COX-2 proteins in macrophage cells using western blotting analysis [20,21]. 
4. Conclusions 
Prior investigation of the genus Sinularia reported on several steroidal glycosides, however, all of 
these were found to possess a 24-methylene substituted side chain [22,23]. 5 is the first example of 
steroidal glycoside with a 23,24-dimethyl substitited side chain from soft coral of the genus Sinularia. 
Our biological data reveal that 2′-O-acetyl-L-fucose functionality plays an important role toward the 
inhibition of the pro-inflammatory iNOS. Steroidal glycoside 2 could be a useful anti-inflammatory 
agent, while steroids 1  and  4  have shown inhibitory activity toward the selected human liver 
cancer cells. 
   Mar. Drugs 2012, 10                                                 
 
 
449 
Acknowledgments 
This work was supported by grants from the National Science Council of Taiwan (NSC98-2113-M-
110-002-MY3) and Ministry of Education (98C031702) awarded to J.-H. S. 
References 
1.  Blunt, J.W.; Copp, B.R.; Munro, M.H.G.; Northcote, P.T.; Prinsep, M.R. Marine natural products. 
Nat. Prod. Rep. 2011, 28, 196–268. 
2.  Su, J.-H.; Ahmed, A.F.; Sung, P.-J.; Chao, C.-H.; Kuo, Y.-H.; Sheu, J.-H. Manaarenolides A–I, 
diterpenoids from the soft coral Sinularia manaarensis. J. Nat. Prod. 2006, 69, 1134–1139. 
3.  Chao, C.-H.; Wen, Z.-H.; Wu, Y.-C.; Yeh, H.-C.; Sheu, J.-H. Cytotoxic and anti-inflammatory 
cembranoids from the soft coral Lobophytum crassum. J. Nat. Prod. 2008, 71, 1819–1824. 
4.  Lu, Y.; Huang, C.-Y.; Lin, Y.-F.; Wen, Z.-H.; Su, J.-H.; Kuo, Y.-H.; Chiang, M.Y.; Sheu, J.-H. 
Anti-inflammatory cembranoids from the soft corals Sinularia querciformis and  Sinularia 
granosa. J. Nat. Prod. 2008, 71, 1754–1759. 
5.  Tseng, Y.-J.; Ahmed, A.F.; Dai, C.-F.; Chiang, M.Y.; Sheu, J.-H. Sinulochmodins A−C, three 
novel terpenoids from the soft coral Sinularia lochmodes. Org. Lett. 2005, 7, 3813–3816. 
6.  Ahmed, A.F.; Su, J.-H.; Kuo, Y.-H.; Sheu, J.-H. Scabrolides E−G, three new norditerpenoids from 
the soft coral Sinularia scabra. J. Nat. Prod. 2004, 67, 2079–2082. 
7.  Ahmed, A.F.; Shiue, R.-T.;  Wang, G.-H.; Dai, C.-F.; Kuo, Y.-H.; Sheu, J.-H. Five novel 
norcembranoids from Sinularia leptoclados and S. parva. Tetrahedron 2003, 59, 7337–7344. 
8.  Sheu, J.-H.; Ahmed, A.F.; Shiue, R.-T.; Dai, C.-F.; Kuo, Y.-H.  Scabrolides  A−D,  four  new 
norditerpenoids isolated from the soft coral Sinularia scabra. J. Nat. Prod. 2002, 65, 1904–1908. 
9.  Radhika, P.; Rao, P.R.; Archana, J.; Rao, N.K. Anti-inflammatory activity of a new sphingosine 
derivative and cembrenoid diterpene (lobohedleolide) isolated from marine soft corals of 
Sinularia crassa Tixier-Durivault and Lobophytum species of the Andaman and Nicobar Islands. 
Biol. Pharm. Bull. 2005, 28, 1311–1313.  
10.  Chao, C.-H.; Chou, K.-J.; Huang, C.-Y.; Wen, Z.-H.; Hsu, C.-H.; Wu, Y.-C.; Dai, C.-F.;  
Sheu, J.-H. Bioactive cembranoids from the soft coral Sinularia crassa. Mar. Drugs 2011, 9, 
1955–1968. 
11.  Radhika, P.; Cabeza, M.; Bratoeff, E.; García,  G. 5α-Reductase inhibition activity of steroids 
isolated from marine soft corals. Steroids 2004, 69, 439–444. 
12.  Kobayashi, M.; Kanda, F.; Damarla, S.R.; Rao, D.V.; Rao, C.B.  Marine  sterols.  XVII. 
polyhydroxysterols of the soft  corals of the Andaman and Nicobar coasts. (2). Isolation and 
structures of three 16β-hydroxy steroidal glycosides from an Alcyonium sp. soft coral. Chem. 
Pharm. Bull. 1990, 38, 2400–2403.  
13.  Kobayashi, M.; Krishna, M.M.; Anjaneyulu, V. Marine  sterols. XXIV. Isolation of   
24-methylenecholestane-1α,3β,5α,6β,16β-pentol from Sinularia sp. of soft coral. Chem. Pharm. 
Bull. 1992, 40, 2845–2846. Mar. Drugs 2012, 10                                                 
 
 
450 
14. Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H. High-field FT NMR application of Mosher’s 
method. The absolute configurations of marine terpenoids.  J. Am. Chem. Soc.  1991,  113,  
4092–4096. 
15.  Cóbar, O.M.; Rodríguez, A.D.; Padilla, O.L.  A  new  steroidal  glycoside from a Caribbean 
gorgonian, Eunicea sp. J. Nat. Prod. 1997, 60, 1186–1188. 
16.  Wang, S.-K.; Dai, C.-F.; Duh, C.-Y. Cytotoxic pregnane steroids from the Formosan soft coral 
Stereonephthya crystalliana. J. Nat. Prod. 2006, 69, 103–106. 
17.  Tanaka, T.; Nakashima, T.; Ueda, T.; Tomii, K.; Kouno, I. Facile Discrimination of aldose 
enantiomers by reversed-phase HPLC. Chem. Pharm. Bull. 2007, 55, 899–901. 
18.  Lu, Y.; Lin, Y.-C.; Wen, Z.-H.; Su, J.-H.; Sung, P.-J.; Hsu, C.-H.; Kuo, Y.-H.; Chiang, M.Y.; Dai, 
C.-F.; Sheu, J.-H.  Steroid and cembranoids from the Dongsha atoll soft coral Lobophytum 
sarcophytoides. Tetrahedron 2010, 66, 7129–7135. 
19.  Alley, M.C.; Scudiero, D.A.; Monks, A.; Hursey, M.L.; Czerwinski, M.J.; Fine, D.L.; Abbott, 
B.J.; Mayo, J.G.; Shoemaker, R.H.; Boyd, M.R. Feasibility of drug screening with panels of 
human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988, 48, 589–601.  
20.  Jean, Y.-H.; Chen, W.-F.; Sung, C.-S.; Duh, C.-Y.; Huang, S.-Y.; Lin, C.-S.; Tai, M.-H.;  
Tzeng, S.-F.; Wen, Z.-H. Capnellene, a natural marine compound derived from soft coral, 
attenuates chronic constriction injury-induced neuropathic pain in rats. Br. J. Pharmacol. 2009, 
158, 713–725.  
21.  Jean, Y.-H.; Chen, W.-F.; Duh, C.-Y.; Huang, S.-Y.; Hsu, C.-H.; Lin, C.-S.; Sung, C.-S.;  
Chen, I.-M.; Wen, Z.-H. Inducible nitric oxide synthase and cyclooxygenase-2 participate in anti-
inflammatory and analgesic effects of the natural marine compound lemnalol from Formosan soft 
coral Lemnalia cervicorni. Eur. J. Pharmacol. 2008, 578, 323–331. 
22.  Anjaneyulu, V.; Rao, K.N.; Radhika, P.; Kobayashi, M. Isolation of 24-methylcholest-5-ene-
3beta,25-diol-3-O-beta-D-arabinopyranoside from Sinularia grandilobata  of Andaman and 
Nicobar Islands. Indian J. Chem. Sect. B 1996, 35, 757–759. 
23.  Anjaneyulu, V.; Rao, P.V.S.; Radhika, P. A new sphingosine derivative and a new polyhydroxy 
steroidal glycoside from Sinularia gravis Tixier-Durivault of the Andaman and Nicobar Islands. 
Indian J. Chem. Sec. B 1999, 38, 357–360. 
Samples Availability: Not available. 
© 2012  by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 